Sève P - Search Results

1

Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.

Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T. Sève P, et al. Clin Cancer Res. 2007 Feb 1;13(3):994-9. doi: 10.1158/1078-0432.CCR-06-1503. Clin Cancer Res. 2007. PMID: 17289895 Clinical Trial.

2

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller EL, Dumontet C. Sève P, et al. Clin Cancer Res. 2005 Aug 1;11(15):5481-6. doi: 10.1158/1078-0432.CCR-05-0285. Clin Cancer Res. 2005. PMID: 16061864

3

Chemoresistance in non-small cell lung cancer.

Sève P, Dumontet C. Sève P, et al. Curr Med Chem Anticancer Agents. 2005 Jan;5(1):73-88. doi: 10.2174/1568011053352604. Curr Med Chem Anticancer Agents. 2005. PMID: 15720263 Review.

4

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.

Sève P, Mackey J, Isaac S, Trédan O, Souquet PJ, Pérol M, Lai R, Voloch A, Dumontet C. Sève P, et al. Mol Cancer Ther. 2005 Dec;4(12):2001-7. doi: 10.1158/1535-7163.MCT-05-0244. Mol Cancer Ther. 2005. PMID: 16373715

5

Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.

Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR. Sève P, et al. Cancer Chemother Pharmacol. 2007 Jun;60(1):27-34. doi: 10.1007/s00280-006-0343-1. Epub 2006 Sep 22. Cancer Chemother Pharmacol. 2007. PMID: 17021819 Clinical Trial.

6

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

Sève P, Dumontet C. Sève P, et al. Lancet Oncol. 2008 Feb;9(2):168-75. doi: 10.1016/S1470-2045(08)70029-9. Lancet Oncol. 2008. PMID: 18237851 Review.

7

The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

Sève P, Reiman T, Dumontet C. Sève P, et al. Lung Cancer. 2010 Feb;67(2):136-43. doi: 10.1016/j.lungcan.2009.09.007. Epub 2009 Oct 13. Lung Cancer. 2010. PMID: 19828208 Review.

8

[Class III beta tubulin expression in nonsmall cell lung cancer].

Sève P, Dumontet C. Sève P, et al. Rev Mal Respir. 2010 Apr;27(4):383-6. doi: 10.1016/j.rmr.2010.03.006. Epub 2010 Mar 25. Rev Mal Respir. 2010. PMID: 20403547 Review. French.

9

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

Sève P, Mackey JR, Isaac S, Trédan O, Souquet PJ, Pérol M, Cass C, Dumontet C. Sève P, et al. Lung Cancer. 2005 Sep;49(3):363-70. doi: 10.1016/j.lungcan.2005.04.008. Lung Cancer. 2005. PMID: 15923058

10

Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.

Sève P, Reiman T, Isaac S, Trillet-Lenoir V, Lafanéchère L, Sawyer M, Dumontet C. Sève P, et al. Anticancer Res. 2008 Mar-Apr;28(2B):1161-7. Anticancer Res. 2008. PMID: 18505052 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

359 results

Search Page

Filters